<DOC>
	<DOCNO>NCT01223937</DOCNO>
	<brief_summary>A multicenter , randomize , double-blind , placebo-controlled , parallel-group trial investigate safety efficacy desmopressin oral melt tablet placebo 3 month treatment adult female nocturia .</brief_summary>
	<brief_title>Investigation Superiority Effect Desmopressin Placebo Terms Night Voids Reduction Nocturia Adult Female Patients</brief_title>
	<detailed_description />
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Written inform consent prior performance trialrelated activity Female sex 18 year age old At least 2 void every night consecutive 3day period screen period 1 . Evidence severe daytime void dysfunction define : Urge urinary incontinence ( 1 episode/day 3day diary period ) Urgency ( 1 episode/day 3day diary period ) Frequency ( 8 daytime voids/day 3day diary period ) 2 . Interstitial cystitis 3 . Urinary retention post void residual volume excess 150 mL confirm bladder ultrasound perform suspicion urinary retention 4 . Habitual psychogenic polydipsia ( fluid intake result urine production exceed 40 mL/kg/24 hour ) 5 . Central nephrogenic diabetes insipidus 6 . Syndrome inappropriate antidiuretic hormone secretion 7 . Current history urologic malignancy e.g . bladder cancer 8 . Genitourinary tract pathology e.g. , infection stone bladder urethra cause symptom 9 . Neurogenic detrusor activity ( detrusor overactivity ) . 10 . Suspicion evidence cardiac failure 11 . Uncontrolled hypertension 12 . Uncontrolled diabetes mellitus 13 . Hyponatraemia : Serum sodium level must within normal limit 14 . Renal insufficiency : Serum creatinine must within normal limit estimate glomerular filtration rate must equal 50 mL/min 15 . Hepatic and/or biliary disease : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) level must twice upper limit normal range . Total bilirubin level must 1.5 mg/dL 16 . History obstructive sleep apnea 17 . Previous desmopressin treatment nocturia 18 . Treatment another investigational product within 3 month prior screen 19 . Concomitant treatment prohibit medication e.g. , loop diuretic ( furosemide , torsemide , ethacrynic acid ) investigational drug 20 . Pregnancy , breastfeeding , plan become pregnant period clinical trial . Subjects reproductive age must documentation reliable method contraception . All preand perimenopausal subject perform pregnancy test . Amenorrhea 12 month ' duration base report date last menstrual period sufficient documentation postmenopausal status require pregnancy test 21 . Known alcohol substance abuse 22 . Work lifestyle may interfere regular nighttime sleep e.g. , shift worker 23 . Any medical condition , laboratory abnormality , psychiatric condition , mental incapacity , language barrier , judgment Investigator , would impair participation trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>